{
    "clinical_study": {
        "@rank": "11542", 
        "arm_group": [
            {
                "arm_group_label": "Keromin Group", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Placebo Group", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "Partial nephrectomy is a widely accepted alternative to radical nephrectomy in patients with\n      clinically localized, unilateral renal cell carcinoma and a normal contralateral kidney.\n      Interruption of renal blood flow via pedicle clamping is often necessary during partial\n      nephrectomy, especially for complex tumors with deep parenchymal invasion.\n      Ischemia-reperfusion injury is a complex process involving several mechanisms including\n      renal vasoconstriction, extensive tubular damage and glomerular injury. The investigators\n      will examine the postoperative renal function of patients who received intraoperative\n      ketorolac and remote ischemic preconditioning during partial nephrectomy."
        }, 
        "brief_title": "Effect of Ketorolac and Remote Ischemic Preconditioning on Renal Ischemia-reperfusion Injury in Patients Undergoing Partial Nephrectomy", 
        "completion_date": {
            "#text": "June 2013", 
            "@type": "Actual"
        }, 
        "condition": "Renal Cell Carcinoma", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Carcinoma, Renal Cell", 
                "Reperfusion Injury"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  ASA l and ll\n\n          -  age 20-65\n\n          -  patients undergoing partial nephrectomy\n\n        Exclusion Criteria:\n\n          -  preoperative liver or renal dysfunction,\n\n          -  coagulopathy,\n\n          -  chronic alcoholism,\n\n          -  hypersensitivity of NSAID,\n\n          -  history of warfarin,\n\n          -  history of gastric ulcer"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "16", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "April 16, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01836406", 
            "org_study_id": "4-2012-0485"
        }, 
        "intervention": {
            "arm_group_label": "Keromin Group", 
            "description": "Ketorolac tromethamine/ single / 1mg/kg/ intravenous administration 30 min before renal artery clamping, remote ischemic preconditioning / 200 mmHg / 5 min inflation and 10 min deflation / 3 cycles / after anesthetic induction", 
            "intervention_name": "Ketorolac tromethamine and remote ischemic preconditioning", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Ketorolac Tromethamine", 
                "Ketorolac"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "ketorolac", 
            "remote ischemic preconditioning", 
            "partial nephrectomy"
        ], 
        "lastchanged_date": "February 17, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of", 
                    "zip": "120-752"
                }, 
                "name": "Severance hospital"
            }
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "South Korea: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "serum creatinine", 
            "safety_issue": "No", 
            "time_frame": "at baseline, 2 hr, 12hr, 24 hr, 48 hr, 72 hr after clamping release"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01836406"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Creatinine clearance", 
                "safety_issue": "No", 
                "time_frame": "at baseline, 2 hr, 12hr, 24 hr, 48 hr, 72 hr after clamping release"
            }, 
            {
                "measure": "urinary NAG", 
                "safety_issue": "No", 
                "time_frame": "at base line, 2 hr, 12 hr after clamping release"
            }, 
            {
                "measure": "serum NGAL", 
                "safety_issue": "No", 
                "time_frame": "at base line, 2 hr, 12 hr after clamping release"
            }
        ], 
        "source": "Yonsei University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Yonsei University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}